Page 6 of 12

PH5.2 | PH5.2 | Cough Pharmacotherapy — SDL Guide — SDL Guide (Part 2)

Antitussives: Central and Peripheral Mechanisms

Antitussives are drugs that raise the threshold of the cough reflex to sub-threshold stimuli, thereby reducing cough frequency without abolishing the protective reflex entirely when stimuli are intense. They are classified by their site of action in the reflex arc.

Central opioid antitussives

Codeine phosphate is the prototype opioid antitussive. It is a pro-drug metabolised in the liver by CYP2D6 to its active form, morphine, which then acts at μ-opioid receptors in the medullary cough centre. The cough-suppressing dose (10–20 mg) is well below the analgesic dose, but it still carries the full spectrum of opioid adverse effects — constipation, nausea, sedation, and at higher doses or in susceptible individuals, respiratory depression. Codeine carries a low but real risk of physical dependence with prolonged use.

The most important safety consideration for codeine is pharmacogenomic variability. Ultra-rapid CYP2D6 metabolisers (a genotype prevalent in North African, Ethiopian, and Middle Eastern populations, and in approximately 1–2% of South Asians) convert codeine to morphine so rapidly that neonatal and paediatric deaths from morphine toxicity have been reported. Codeine is therefore absolutely contraindicated in children <12 years and in breastfeeding mothers (ultra-rapid metaboliser mothers expose nursing infants to dangerously high morphine concentrations in breast milk). Codeine is also contraindicated in adolescents aged 12–18 years who have had tonsillectomy for obstructive sleep apnoea — a regulatory restriction in many countries.

Pholcodine is a closely related opioid antitussive with less analgesic effect and lower dependence potential than codeine. It is no longer available in some countries due to concerns about sensitisation to neuromuscular-blocking agents (a cross-reactivity mechanism under investigation). Mechanism: μ-opioid receptor agonism at the medullary cough centre, similar to codeine but with less CYP2D6-dependent activation.

Central non-opioid antitussives

Dextromethorphan (DXM) is the most widely used over-the-counter antitussive. Its mechanism is not opioid — it is an NMDA (N-methyl-D-aspartate) receptor antagonist and a sigma-1 receptor agonist. It is not analgesic at standard antitussive doses (15–30 mg three to four times daily) and does not cause physical dependence at therapeutic doses. Its efficacy is comparable to codeine in clinical trials, and placebo-controlled trials for acute cough show a modest but real benefit over placebo.

The most clinically important adverse effect of dextromethorphan is serotonin syndrome, which occurs when it is combined with drugs that increase serotonergic activity — particularly monoamine oxidase inhibitors (MAOIs) and selective serotonin reuptake inhibitors (SSRIs). DXM weakly inhibits serotonin reuptake; combined with a MAOI (phenelzine, tranylcypromine, or within 14 days of stopping a MAOI) the combination can cause life-threatening serotonin toxicity. This combination is absolutely contraindicated. With SSRIs, the risk is lower but real; caution and dose minimisation are required. High-dose DXM abuse ('robo-tripping') produces dissociative effects consistent with its NMDA antagonism — a pharmacological reality that should not enter standard dosing.

Noscapine is a benzylisoquinoline alkaloid from the opium poppy (structurally distinct from the morphine analgesics) with antitussive properties but no significant analgesic effect, no respiratory depression at therapeutic doses, and no dependence potential. Its exact mechanism of central cough suppression is not fully elucidated but may involve peripheral C-fibre effects as well as central actions. Noscapine is widely used in India (as per Tripathi) and is considered safe in adults; it is sometimes preferred over codeine for this reason.

Peripheral antitussives

Benzonatate acts as a local anaesthetic on vagal afferent nerve endings in the respiratory tract — it is related to tetracaine and anaesthetises the stretch receptors (RARs) that initiate the reflex. It therefore acts peripherally and has minimal CNS effects at therapeutic doses. It is available as soft gel capsules that must be swallowed whole; chewing or crushing releases the local anaesthetic in the mouth and can cause numbness, aspiration risk, and rare cardiac toxicity.

Levodropropizine suppresses cough by acting on peripheral opioid-like receptors (not classical μ/κ/δ receptors) on C-fibre afferents, reducing their sensitivity without any central opioid effects. It does not cause sedation or respiratory depression and is particularly useful when central antitussive side-effects need to be avoided (elderly patients, patients needing to remain alert). It is commonly used in Italy and some Asian markets.

Expectorants and Mucolytics

Expectorants and mucolytics are used in productive cough to facilitate the clearance of tenacious or excess secretions. They differ in their mechanisms and the nature of their effect on mucus.

Expectorants work by increasing the volume of airway secretions or by reducing their apparent viscosity through dilution. They do not directly break chemical bonds within mucin.

Guaifenesin (glyceryl guaiacolate) is the most widely used expectorant globally and the active ingredient in many OTC products. Its proposed mechanism involves a gastro-pulmonary vagal reflex — small doses irritate the gastric mucosa, triggering a vagal reflex that increases bronchial secretion volume and stimulates ciliary activity. The net effect is a more hydrated, less viscous secretion that is easier to expectorate. Clinical trial evidence for efficacy in acute bronchitis is modest and inconsistent; it is safe, well-tolerated, and widely used. Adverse effects at standard doses are minimal — nausea at high doses. It is the preferred expectorant during pregnancy (Category C; less evidence of harm than alternatives).

Ammonium chloride and potassium iodide are older expectorants that also act via a gastric irritation mechanism (reflex hypersecretion). They are rarely used as first-line agents today; ammonium chloride is nephrotoxic in high doses and potentiates metabolic acidosis; potassium iodide can cause thyroid dysfunction (hypothyroidism or hyperthyroidism — especially in patients with pre-existing thyroid disease) and iodism (metallic taste, hypersalivation, parotid swelling, skin rashes) with prolonged use. Both remain available in compound preparations in many markets.

Drug	Mechanism	Key ADR	Notes
Guaifenesin	Reflex secretion ↑	Nausea (high dose)	Preferred in pregnancy
Ammonium chloride	Reflex secretion ↑	Metabolic acidosis, nephrotoxicity	Avoid in renal/hepatic disease
Potassium iodide	Reflex secretion ↑	Thyroid dysfunction, iodism	Avoid in thyroid disease

Mucolytics directly reduce the viscosity of mucus by disrupting the molecular architecture of mucin glycoproteins.

NAC (N-acetylcysteine) is the archetype mucolytic. It works by cleaving disulfide bonds between mucin glycoprotein chains, reducing mucus viscosity and elasticity and making it easier to expectorate. NAC is also a glutathione precursor and a potent antioxidant — the basis for its use as the antidote for paracetamol (acetaminophen) overdose at much higher doses than its mucolytic dose. For respiratory mucolysis, it is given orally (200–600 mg two to three times daily, Tripathi) or by inhalation (nebulised solution). In high-dose long-term use, it has been shown in trials to modestly reduce exacerbation frequency in COPD (though this remains an off-label use in most markets). Adverse effects include nausea, vomiting, and — when nebulised — bronchospasm (pre-treat with a bronchodilator; NAC releases free cysteine which can be irritant). Carbocisteine (S-carboxymethylcysteine) has a similar mechanism (cleaving disulfide bonds) and is widely used in Europe and Asia.

Bromhexine is a synthetic derivative of vasicine (from Adhatoda vasica). Its mechanism is mucokinetic: it reduces the viscosity of mucus by stimulating serous (non-mucous) gland secretion (diluting the viscous mucin layer) and by reducing the production of high-viscosity mucin by goblet cells. Unlike NAC, it does not directly cleave disulfide bonds. Ambroxol is the active metabolite of bromhexine and is more potent; it also stimulates pulmonary surfactant synthesis — a useful adjunct property in preterm infants at risk of respiratory distress syndrome. Both agents are well-tolerated; mild GI upset is the main adverse effect.

Erdosteine is a prodrug that is hydrolysed in the body to release an active thiol-containing metabolite that cleaves mucin disulfide bonds (similar to NAC). It also has anti-inflammatory and antioxidant properties. It is available in some markets as an alternative mucolytic in COPD patients.

Hydration is not a pharmacological agent but is the single most effective measure to reduce mucus viscosity — systemic dehydration thickens secretions. Adequate fluid intake (>1.5–2 L/day unless contraindicated) should be prescribed alongside every mucolytic or expectorant.

Clinical Decision-Making in Cough Management

Rational cough management requires integrating the pathophysiology, the drug-class taxonomy, and the patient-specific context into a prescribing decision. A structured clinical algorithm prevents the most common errors.

Step 1: Characterise the cough. Is it dry (non-productive) or productive? Productive cough produces sputum — the colour, volume, and consistency matter. Purulent sputum (yellow or green) suggests bacterial or viral infection; frothy pink-tinged sputum suggests pulmonary oedema. Dry cough is irritant, tickling, without sputum. This single assessment determines the entire pharmacotherapy branch.

Step 2: Identify the likely cause. In non-smokers with a normal chest X-ray, the three most common causes of chronic cough (>8 weeks) are post-nasal drip (upper airway cough syndrome), GERD, and cough-variant asthma — together responsible for >90% of cases (Irwin's triad). In acute cough (<3 weeks), URTI is the most common cause. In smokers, consider COPD or lung malignancy. In patients on ACE inhibitors, consider ACE-I cough (occurs weeks to months after starting; resolves within 1–4 weeks of stopping).

Step 3: Treat the cause first; add symptomatic therapy second.

Clinical scenario	First-line	Symptomatic add-on (if needed)
Dry cough, URTI — acute	Saline gargle, demulcent	DXM or codeine at night only
ACE-inhibitor cough	Switch to ARB	None — resolves with drug change
Post-nasal drip / allergic rhinitis	INCS (fluticasone nasal spray) ± 1st-gen antihistamine	—
GERD-induced cough	PPI for 8 weeks	—
Cough-variant asthma	Inhaled corticosteroid ± SABA	—
Productive cough — LRTI/COPD exacerbation	Treat infection ± appropriate antibiotic; mucolytic (bromhexine/NAC)	Never antitussive

Special populations:

• Paediatrics (children <12 years): Codeine and all opioid-containing antitussives are contraindicated (CYP2D6 variability; opioid toxicity deaths). Dextromethorphan is generally avoided below age 4. Honey (not under 1 year — risk of infantile botulism) is WHO-recommended as first-line for nocturnal cough in children aged 1–5; it is non-inferior to DXM in RCTs (Paul et al., 2007). Demulcents and saline nasal rinse are the backbone of paediatric cough management.

• Pregnancy: Codeine should be avoided (especially in the 1st trimester; risk of neonatal withdrawal and CYP2D6 variability). Dextromethorphan is considered relatively safe in the second and third trimesters (no teratogenicity in human studies); it is the preferred antitussive if one is needed. Guaifenesin is the preferred expectorant (widely used). Avoid potassium iodide (thyroid risk to the foetus).

• Elderly patients: Central antitussives (especially codeine) increase risk of respiratory depression, sedation, falls, and constipation. Peripheral agents (benzonatate, levodropropizine) or demulcents are preferred. NAC or bromhexine are safe mucolytics in the elderly but monitor renal function (dose adjustment in severe renal impairment).

• Patients on multiple medications: Screen for MAOI/SSRI use before recommending DXM; check for CYP2D6 inhibitors (fluoxetine, paroxetine) in patients on codeine — these drugs can convert extensive metabolisers effectively into poor metabolisers, reducing codeine efficacy.

Self-Assessment: Cough Pharmacotherapy

Use these clinical scenarios to test your application of cough pharmacotherapy principles before reviewing the answers.

Scenario A: A 55-year-old man with hypertension has been on ramipril (an ACE inhibitor) for 6 months. He presents with a persistent dry, tickling cough that began 3 months after starting ramipril. He has no sputum, normal chest examination, and normal spirometry. He asks whether a cough syrup would help.

What is the most appropriate management? The cough is ACE-inhibitor-induced (bradykinin accumulation, a class effect). The correct action is to switch ramipril to an ARB (e.g. losartan, valsartan) — ARBs do not inhibit bradykinin breakdown. The cough will resolve within 1–4 weeks of switching. No antitussive is appropriate — it will not address the cause and will require indefinite prescribing.

Scenario B: A 60-year-old man presents with a 2-week history of worsening cough with increasing volume of purulent green sputum. He has a 30-pack-year smoking history. Examination reveals coarse crackles at the right base. He is diagnosed with an acute exacerbation of COPD with probable bacterial bronchitis.

What class of cough medication is indicated? A mucolytic (e.g. bromhexine 8 mg three times daily or NAC 600 mg once or twice daily) to reduce secretion viscosity and facilitate clearance, alongside appropriate antibiotic therapy. Antitussives are absolutely contraindicated — suppressing the cough would prevent clearance of the infective secretion load and risk atelectasis.

Scenario C: A 19-year-old student has been taking sertraline (an SSRI) for 8 months for anxiety. He develops a dry cough and visits a pharmacy for an OTC remedy. The pharmacist recommends a preparation containing dextromethorphan 15 mg per dose.

What drug interaction concern should be raised? Dextromethorphan weakly inhibits serotonin reuptake; combined with an SSRI (sertraline), there is a risk of serotonin syndrome — particularly at higher doses or in CYP2D6 poor metabolisers who accumulate DXM. The interaction is real but generally lower risk than with MAOIs. The pharmacist should counsel the patient to use the lowest effective dose, limit duration, and seek medical attention if symptoms of serotonin toxicity develop (agitation, tremor, hyperreflexia, diaphoresis). An alternative approach is benzonatate or a demulcent (honey or simple linctus).